Although SALF-mediated immune responses and regulation of MAPK and NF-κB pathways have been well documented [33,34,35], such modulation of the levels of chemokines and cytokines by our vaccine (SALF in conjunction with inactivated MBT-2 lysate) for desired cancer immunity is unprecedented. Here, NFKB1 is linked to cancer.